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Abstract
Purpose Nelson’s syndrome is a challenging condition that can develop following bilateral adrenalectomy for Cushing’s 
disease, with high circulating ACTH levels, pigmentation and an invasive pituitary tumor. There is no established medi-
cal therapy. The aim of the study was to assess the effects of pasireotide on plasma ACTH and tumor volume in Nelson’s 
syndrome.
Methods Open labeled multicenter longitudinal trial in three steps: (1) a placebo-controlled acute response test; (2) 1 month 
pasireotide 300–600 μg s.c. twice-daily; (3) 6 months pasireotide long-acting-release (LAR) 40–60 mg monthly.
Results Seven patients had s.c. treatment and 5 proceeded to LAR treatment. There was a significant reduction in 
morning plasma ACTH during treatment (mean ± SD; 1823 ± 1286 ng/l vs. 888.0 ± 812.8 ng/l during the s.c. phase vs. 
829.0 ± 1171 ng/l during the LAR phase, p < 0.0001). Analysis of ACTH levels using a random intercept linear mixed-
random effects longitudinal model showed that ACTH (before the morning dose of glucocorticoids) declined significantly 
by 26.1 ng/l per week during the 28-week of treatment (95% CI − 45.2 to − 7.1, p < 0.01). An acute response to a test dose 
predicted outcome in 4/5 patients. Overall, there was no significant change in tumor volumes (1.4 ± 0.9 vs. 1.3 ± 1.0, p = 0.86). 
Four patients withdrew during the study. Hyperglycemia occurred in 6 patients.
Conclusions Pasireotide lowers plasma ACTH levels in patients with Nelson’s syndrome. A longer period of treatment may 
be needed to assess the effects of pasireotide on tumor volume.
Trial registration: Clinical Trials.gov ID, NCT01617733
Keywords Nelson’s · Pasireotide · Medical therapy · Corticotroph pituitary adenoma
Introduction
Nelson’s syndrome is a very challenging condition that 
can develop following bilateral adrenalectomy (BLA) for 
Cushing’s disease (CD), and is due to the development 
of a progressive tumor of the corticotroph cells in the 
pituitary [1]. It occurs in up to 30% of patients with CD Electronic supplementary material The online version of this 
article (https://doi.org/10.1007/s11102-017-0853-3) contains 
supplementary material, which is available to authorized users.
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undergoing bilateral adrenalectomy [2] although progres-
sion of the size of a corticotroph tumor as assessed by MRI 
is more common and is detected in 50% of patients within 
10 years of BLA for CD [3, 4]. The corticotroph tumor 
may be small in some cases but may also be extensive 
and locally invasive in others; patients can present with 
mass effects, headache, visual field defects, and external 
ophthalmoplegia [5, 6]. The hallmarks of the syndrome 
are skin hyperpigmentation and high plasma adrenocorti-
cotropic hormone (ACTH) levels that reflect the activity 
of the tumor and are used for monitoring [7]. Treatment of 
Nelson’s is restricted to pituitary surgery and radiotherapy 
only when there is an amenable anatomic target and the 
patient’s condition allows [8–10]. In many patients with 
Nelson’s syndrome these conditions are not met; the levels 
of ACTH continue to rise, the symptoms persist and there 
are limited treatment options.
There is currently no medical therapy that can consist-
ently reduce plasma ACTH levels and corticotroph tumor 
growth, and there is a real need for an effective medical man-
agement for Nelson’s syndrome. The anti-epileptic sodium 
valproate was frequently used in the past with disappointing 
or variable results [11–16] and dopamine agonists such as 
cabergoline only occasionally result in satisfactory response 
[17–20]. Peroxisome proliferator-activated receptor gamma 
(PPARγ) agonists such as rosiglitazone have also been stud-
ied: one report showed biochemical response in two out of 
three patients, but one of these subsequently escaped [21]. 
Our group previously showed that even high doses of rosigli-
tazone (12 mg/day) do not reduce plasma ACTH levels [5]. 
Temozolomide is a medical treatment for aggressive pitui-
tary tumors, but is associated with significant toxicity limit-
ing its use [22].
Pasireotide exerts its pharmacologic effects by binding 
and activating multiple somatostatin receptor subtypes (1, 2, 
3, and 5). In vitro experiments have shown that pasireotide 
inhibits ACTH secretion in cultured corticotroph adenoma 
cells [23] and prospective clinical trials have proved effec-
tiveness in lowering cortisol levels in patients with active 
Cushing’s disease [24–26]. More recently, pasireotide LAR 
was used to treat a patient with an invasive corticotroph 
tumor resulting in clinical improvement, and reductions in 
tumor size and plasma ACTH levels [27].
In light of these data we have performed a prospective 
multicenter clinical study aiming to investigate the effects 
of pasireotide on circulating plasma ACTH and tumor size 
in patients with Nelson’s syndrome. In particular, the study 
was structured to assess: (1) the acute effects of pasireotide 
on circulating levels of plasma ACTH after a single 600 μg 
s.c. injection, and whether this would allow prediction of 
individual longer-term response, (2) the effects of 4-week 
of pasireotide s.c. on circulating plasma ACTH, (3) the 
effects of pasireotide LAR given monthly for 6 months on 
circulating plasma ACTH, and (4) the effect of pasireotide 
s.c. and LAR on tumor volume.
Methods
Study design
This was an open labeled longitudinal trial over a 31-week 
period conducted in four tertiary centers in England, UK. 
As there is currently no alternative treatment for Nelson’s 
syndrome, no control group was used. There were three 
parts to the study. Initially, an acute response of plasma 
ACTH to pasireotide was assessed in a placebo-controlled 
randomized single-blinded crossover intervention where 
patients received either a test dose of 600 μg pasireotide 
s.c. or an equivalent volume of saline s.c. whilst omit-
ting their glucocorticoid treatment to establish if an acute 
response predicts future efficacy. In the second part of the 
study, patients received short-term (4-week) open label 
treatment with pasireotide twice-daily s.c. (600 μg b.d. 
or 300 μg b.d. if dose reduction due to tolerability was 
necessary). In the last part of the study patients had long-
term open label treatment with pasireotide LAR 60 mg 
(or 40 mg if reduced for tolerability) every 28 days for 24 
weeks (Fig. 1).
Fig. 1  Pasireotide treatment in Nelson’s syndrome: study design
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Study endpoints
Primary endpoint
Early morning plasma ACTH sampled before (0 h), and 
2 h after morning glucocorticoid (GC) replacement dur-
ing 4 weeks of pasireotide s.c. 1200 μg/day (or 600 μg/
day if reduced for tolerability issues) compared with levels 
at these respective time points found at baseline and after 
6-months depot pasireotide LAR i.m. every 28 days. The 
response criteria were defined according to the fall in plasma 
ACTH prior to first morning dose of GC or the fall in plasma 
ACTH 2 h after the morning dose of GC. Complete success 
was defined as a fall in pre-GC plasma ACTH > 400 ng/l, 
or fall of > 200 ng/l 2 h after GC; partial success a fall in 
pre-GC plasma ACTH < 399 ng/l > 200 ng/l, or 2 h after 
GC < 199 ng/l > 100 ng/l; and not successful a fall in pre-
GC plasma ACTH < 199 ng/l, or 2 h after GC < 99 ng/l. The 
baseline value of the pre-GC ACTH was the mean of 4 val-
ues (from visits 1 to 4). The baseline of the post-GC ACTH 
was the value from visit 1 (screening visit).
Secondary endpoints
(1) Plasma ACTH before and at 2, 3, 4, 5, and 6 h after 
an acute single dose of 600 μg pasireotide or saline. (2) 
Changes in tumor volume at the end of the study determined 
by MRI. (3) Changes in skin pigmentation at the end of 
the study period compared with pre-treatment. (4) Change 
in HbA1c, fasting insulin and glucose levels during pasire-
otide s.c. and LAR treatment. (5) Tolerability and safety of 
pasireotide.
Patients
Patients with Nelson’s syndrome were eligible to take part in 
this study. All patients gave informed consent and the study 
was approved by the UK Health Research Authority (ref 
10/H1005/53). The inclusion criteria were: male or female 
patients aged 18–80 years with signs, symptoms and bio-
chemistry consistent with Nelson’s syndrome and a negative 
pregnancy test (where applicable). The exclusion criteria 
were: (1) pituitary radiotherapy within the last year prior 
to study entry, (2) recent significant deterioration in visual 
fields or other neurological signs related to tumor mass 
requiring surgery, (3) severe liver disease, (4) symptomatic 
cholelithiasis, (5) clinically significant abnormal laboratory 
values, (6) a QTcF interval measured on the EKG > 480 ms, 
(7) pregnancy or lactation, (8) recent (last 6 months) history 
of alcohol or drug abuse, (9) concurrent administration of 
investigational drug for another study, (10) history of non-
compliance, or inability to complete the entire study for any 
reason. Skin pigmentation was assessed at screening, at the 
start and at the end of pasireotide LAR treatment. Patients 
received no previous medical treatment for NS; patient char-
acteristics are provided in the Supplementary Table.
Measurements
Imaging
Gadolinium-enhanced MRI of the pituitary was performed at 
the participating centers before and after treatment to assess 
the tumor volume. A blinded radiologist assessed the scans 
using standard volumetric techniques [28–30]. Abdominal 
USS was performed at screening and at the end of the study 
to assess for the presence of cholelithiasis.
Skin pigmentation
An assessment of the pigmentation by the attending phy-
sicians and medical photographs of participants were per-
formed at screening, at the start, and at the end of pasireotide 
LAR treatment. The photographs of all participants were 
collected and analyzed centrally.
Assays
Fasting insulin and ACTH samples were collected and ana-
lyzed at the central Clinical Chemistry laboratory. Insulin 
was measured with the Roche electrochemiluminescence 
immunoassay on a cobas e602 module (reference range 
17.8–173 pmol/l, CV 1.8 and 2.5% at values of 121 and 
2062 pmol/l). ACTH was measured by chemiluminescent 
immunometric assay on the Siemens Immulite 2000 analyzer 
(reference range < 46 ng/l at 9 a.m. and < 15 ng/l at mid-
night, CV 5.56 and 6.94% at values of 26.2 and 382 ng/l).
Statistical analysis
Sample size
A target of 17 patients was calculated taking into account 
the variability of ACTH levels and a 13% dropout rate 
which was recorded for a pasireotide phase 2 study [31]. 
Accounting for a within person variability of ACTH levels 
of approximately 400 ng/l for the pre-GC dose and 250 ng/l 
post-GC dose, 15 patients were needed to detect a clinically 
significant change of 200 ng/l with a power of 80% with 
5% significance and a further two patients to cover possible 
dropout [5].
Statistical analysis was performed using GraphPad (6.0d 
GraphPad Software, La Jolla California USA), SPSS v22 
(IBM Corp., Armonk, NY) and STATA (StataCorp., College 
Station, TX: StataCorp LP). The main aim of the analysis 
was to establish whether ACTH levels change over time after 
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pasireotide therapy. ACTH levels at 0 h (before morning 
glucocorticoid dose) and 2-post GC dose, were compared 
before onset of pasireotide treatment (‘baseline’), during 
s.c. and LAR pasireotide treatment using the Kruskal–Wal-
lis non-parametric test; results are reported in mean ± SD. 
Baseline ACTH levels at 0 h were compared with baseline 
ACTH levels at 2 h using a two tailed Mann–Whitney non-
parametric test. For the acute response test we calculated the 
relative decrease of ACTH levels at 2, 3, 4, 5, and 6 h after a 
single s.c. pasireotide dose from the mean pre-dose ACTH 
levels (time points were at − 1, − 0.5 and 0 h before dose) 
as well as a mean relative decrease. Comparison of safety 
blood tests was with one-way ANOVA. The longitudinal 
data (ACTH levels) were analyzed using a linear mixed-ran-
dom effects model. We report estimates for the coefficient(s) 
from these regression models along with their associated 
95% confidence interval (CI). Tumor volumes before and 
after treatment were compared by paired t-test, assuming a 
normal distribution; results are reported in mean ± SD. A p 
value < 0.05 was considered statistically significant.
Results
Patients
Eight patients were recruited, all females. Of the eight 
patients, two withdrew during the s.c. phase (1, 8) and two 
in the LAR phase of treatment (5, 7) and 4 patients (2, 3, 4, 
6) completed all of the study visits (Table 1). In all patients 
any radiotherapy had been administered at least 5 years prior 
to study entry. Patient 1 withdrew after 11 days of s.c. pasire-
otide 1200 μg b.d. due to abdominal cramps (resolved after 
stopping pasireotide). Patient 5 withdrew after completing 
the s.c. phase. Patient 7 withdrew during the LAR phase 
due to significant hyperglycemia that persisted at the end 
of the study visit 2 months after stopping pasireotide but 
improved to baseline on longer follow-up after study com-
pletion. Patient 8 withdrew during the first visit of the s.c. 
phase due to adverse events (felt unwell, drowsy, had a head-
ache and was hypotensive during the visit); ACTH sampling 
from this visit was incomplete and therefore ACTH levels 
from this patient were not included in the statistical analysis.
Plasma ACTH levels improved during pasireotide 
treatment
ACTH levels at 0 h prior to the morning glucocorticoid 
dose (ACTH 0 h) at baseline were compared with ACTH 
0  h levels during the s.c. phase and ACTH 0  h levels 
during the LAR phase. Overall, there was a significant 
reduction in ACTH 0  h during treatment (mean base-
line 1823 ± 1286 ng/l vs. 888.0 ± 812.8 ng/l during the 
s.c. phase vs. 829.0 ± 1171 ng/l during the LAR phase, 
p < 0.0001, H = 20.93 mean ranks 57.3 vs. 37.5 vs. 29.8) 
(Fig. 2). Similarly, comparison of ACTH levels 2 h after the 
morning glucocorticoid dose showed reduction of ACTH 
2 h levels during the two treatment phases (mean baseline 
1100 ± 987 vs. 490.0 ± 460.3 ng/l during the s.c. phase 
vs. 262.2 ± 219.4 ng/l during the LAR phase, p = 0.001, 
H = 13.38 mean ranks 40.2 vs. 31.1 vs. 21.1). Baseline 
ACTH levels at 0 and 2 h post glucocorticoid dose were 
significantly different (p = 0.04). In order to investigate 
the change of ACTH levels over time, plasma ACTH (0 h 
pre-GC and 2 h post-GC) at each study visit and for each 
individual patient were analyzed using a marginal General-
ized Linear Model (GLM) for longitudinal data. There was 
a statistically significant decline in the ACTH 0 h pre-GC 
Table 1  Summary of response to pasireotide treatment
C complete success, P partial success, No no success (for definitions please refer to Methods)
*Pre-test ACTH is the average of 3 time-points (− 1, − 0.5, 0 h) and post test average calculated from ACTH levels at 2, 3, 4, 5, and 6 h after 
600 μg pasireotide s.c.
Patient ID Acute response test s.c. phase LAR phase
Relative decrease in 
plasma ACTH levels*
Daily dose (μg) Treatment time Response* Monthly dose (mg) Treatment time Response*
1 – 1200 11 days C – – –
2 79% 1200 4 weeks C 60 24 weeks C
3 25% 600 4 weeks C 40 24 weeks No
4 84% 600 4 weeks C 40 24 weeks C
5 53% 1200 4 weeks C – – –
6 − 16% 1200 4 weeks P 60 24 weeks C
7 70% 1200 4 weeks P 60 12 weeks P
8 – 1200 0.5 day No – – –
Protocol 2-week 4-weeks 24-weeks
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levels throughout the study; ACTH 0 h levels declined by 
26.1 ng/l per week (95% CI − 45.2 to − 7.1; p < 0.007). GLM 
analysis showed that plasma ACTH 2 h post-GC levels did 
not significantly change over time; ACTH 2 h levels declined 
by 4.0 ng/l per week, 95% CI − 12.58 to 4.49, p = 0.35.
Applying the a priori ACTH response criteria at the end 
of 4-week of s.c. pasireotide (or at the last visit if patient 
withdrew prior to the end of this phase) 5/8 patients had 
a complete response, 2/8 had a partial response while one 
patient did not respond (Table 1). The patient who did not 
respond withdrew very early from the study after one s.c. 
dose of pasireotide (patient 8). At the end of 24-week of 
pasireotide LAR treatment or at the last visit, 3/5 patients 
had a complete response, 1/5 a partial response and 1/5 
showed no response. Four patients completed the study; 3/4 
had a complete response at the end of the study and 1/4 
did not respond (Table 1). Overall, 6/8 patients had com-
plete or partial responses at their last biochemical assess-
ment (either at the end of the study or last visit before with-
drawal) (Fig. 3). There was no clear relationship between 
dose administered and effect.
Acute response to pasireotide test dose
Six patients received the pasireotide/placebo test dose while 
omitting their glucocorticoid treatment (Fig. 4); 5/6 patients 
showed a consistent reduction in plasma ACTH levels and 
one (patient 6) did not respond (patient 4 received her usual 
glucocorticoid dose during the test and is excluded). The 
mean relative decrease in plasma ACTH levels before and 
2-6hours after a pasireotide test dose in the five patients 
who showed a positive response to the test was between 25 
and 84% (patient 2—79%, patient 3—25%, patient 4—84%, 
patient 5—53%, patient 7—70%); all patients with a positive 
acute response (i.e. reduction in ACTH levels post pasire-
otide test dose) showed a positive response at the s.c. phase 
of treatment. The maximum reduction was observed between 
4 and 6 h for all patients; those with a maximum relative 
decrease of at least 42% of their baseline ACTH levels fol-
lowing a test dose showed some response (complete or par-
tial) to pasireotide treatment.
Change in tumor volume and skin pigmentation
Tumor volume
Five patients had MRIs at screening and at the end of the 
study; four patients completed the 28-week of the treatment 
protocol (patients 2, 3, 4, 6) and one patient (patient 7) with-
drew during the LAR phase. Overall, there was no signifi-
cant change in tumor volumes between the pre-treatment and 
post-treatment scans (1.4 ± 0.9 vs. 1.3 ± 1.0, p = 0.86).
Skin pigmentation
There was no evidence of a change in skin pigmentation 
during the study as assessed by the independent assessor, 
although the attending physicians at the centers felt there 
was an improvement in 3 patients (patients 3, 6, 7).
Hyperglycemia during treatment
Fasting blood glucose and Hba1c increased during therapy 
and 6 patients developed hyperglycemia (Fig. 5). Fasting 
glucose: mean at baseline 4.6 ± 0.6 vs. 6.9 ± 1.6 mmol/l 
during s.c. phase vs. 9.6 ± 2.9 mmol/l during LAR phase, 
p < 0.01, Hba1c in mmol/mol: mean at baseline 42.9 ± 7.8 
vs. 45.6 ± 8.5 during s.c. phase vs. 60.0 ± 13.6 during LAR 
phase, p < 0.01. Patient 7 withdrew from the study due to 
significant hyperglycemia after 16 weeks of treatment. 
Fig. 2  Mean plasma ACTH at 0 h prior to the morning dose of glu-
cocorticoids improved during pasireotide treatment (mean baseline 
1823 ± 1286 ng/l vs. 888.0 ± 812.8 ng/l during the s.c. phase and vs. 
829.0 ± 1171 ng/l during the LAR phase, p < 0.0001)
Fig. 3  Individual plasma ACTH changes during the study in eight 
patients (ACTH levels before the morning dose of hydrocortisone)
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Fasting insulin levels reduced during s.c. and LAR pasire-
otide treatment (mean baseline 118.1 ± 23.70 vs. mean dur-
ing s.c. treatment 51.09 ± 12.52 vs. 64.94 ± 111.90 during 
LAR phase, p = 0.04).
Adverse events
During the study the majority of patients reported diar-
rhea (7 patients), nausea and headaches (6 patients), 
dizziness (5), abdominal cramps (4), flu-like symptoms 
(4) and symptoms of hyperglycemia (4). There were no 
events attributed to cholelithiasis, no clinically significant 
events relating to baseline blood tests (electrolytes, renal 
and liver function tests).
(a) (b) (c)
(d) (e) (f)
Fig. 4  Acute response of plasma ACTH levels to a single dose of pasireotide 600 μg s.c. in 7 patients [Patients a 2, b 3, c 4, d 5, e 6, f 7]
a b
Fig. 5  a Mean fasting glucose increased during pasireotide treatment 
(values from 7 patients included in the baseline mean value and s.c. 
phase, 5 patients for the LAR phase). b Mean HbA1c levels increased 
during pasireotide treatment (values from 7 patients during s.c. phase 
and 5 patients during LAR phase)
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Discussion
Nelson’s syndrome affects a significant number of patients 
treated with bilateral adrenalectomy for the management 
of hypercortisolism associated with Cushing’s disease, and 
can be severely debilitating and life threatening. Although 
Nelson’s syndrome is a condition that may be anticipated 
to occur after BLA, it poses a significant clinical man-
agement challenge, as there is currently no medical treat-
ment that works consistently. In this prospective clinical 
study we have shown that pasireotide significantly reduces 
plasma ACTH levels in patients with Nelson’s syndrome. 
All 7 patients treated with s.c. pasireotide (600 or 300 μg 
b.d.) had a significant reduction in plasma ACTH levels 
and 4 out of 5 patients who progressed to receive monthly 
LAR pasireotide treatment continued to show a biochemi-
cal response. Pasireotide could, therefore, be considered 
for the treatment of patients with Nelson’s syndrome 
especially if there is positive biochemical response to s.c. 
pasireotide after a short 4-week treatment trial. Following 
this period patients that respond could continue on s.c. 
treatment or change to monthly LAR administration.
In this 28-week study there were no conclusive changes 
in either skin pigmentation or tumor volume, although 
there was an indication of possible improvement in pig-
mentation in 3/7 patients and there was at least one patient 
with minimal improvement in tumor volume. It is reason-
able to anticipate that a biochemical response would be 
followed by a reduction in tumor volume on long-term 
treatment and our negative findings could be due to the 
small patient numbers or the short duration of treatment. A 
reduction of tumor volume with pasireotide treatment has 
been documented in patients with CD [24, 32] and a case 
report of a patient with Nelson’s syndrome treated with 
pasireotide LAR [27]; similar to our findings, the reduc-
tion in ACTH in this case report was evident early, within 
1 month of treatment with improvement of skin hyper-
pigmentation. Tumor shrinkage is also well documented 
in patients with acromegaly treated with first and second 
generation somatostatin analogs [33]. A longer period of 
treatment is needed to fully assess the effects of pasire-
otide on tumor volume in Nelson’s syndrome.
In the advent of personalized medicine, predicting 
which patients are more likely to benefit from pasireotide 
treatment is extremely desirable as it could avoid expen-
sive unnecessary treatment trials and exposure of patients 
to potential side effects. A positive acute response to pasir-
eotide test dose (i.e. reduction in plasma ACTH levels fol-
lowing a single 600 μg s.c. dose) may predict response 
to long-term treatment in the majority of patients, but a 
negative response does not exclude that a response will be 
seen; 5 out of 6 patients who had a consistent reduction in 
plasma ACTH after a test dose had a response to pasire-
otide treatment. Furthermore, patients that exhibited a 
decrease of plasma ACTH by at least 42% from baseline 4 
to 6 h after a pasireotide test dose showed some response 
(partial or complete) to pasireotide treatment. Histo-
pathological analysis of tissue samples in patients with 
prior pituitary surgery looking specifically at the expres-
sion of somatostatin receptors (SSTR) could be assessed 
as a factor for predicting responsiveness. Unfortunately 
the historical histological samples in this study were not 
available for re-examination but correlation of the SSTR 
expression patterns and biochemical response would have 
been interesting to examine and could help explain the 
differences in response between patients. However, it is 
also possible that SSTR expression from the original cor-
ticotroph tumor is different than the active Nelson’s tumor, 
and potentially this might be affected by other modalities 
of therapy, including radiotherapy. Furthermore, recent 
molecular studies in patients with CD suggest that there is 
enhanced SSTR5 mRNA expression in corticotroph adeno-
mas harboring somatic mutations of the USP8 gene, and 
it is possible that the presence of USP8 mutations could 
help predict response to pasireotide treatment in Nelson’s 
tumors [34]. In our study no clear dose response relation-
ship was observed on the effect on plasma ACTH. This 
may be due to varying expression of somatostatin recep-
tors in the tumors or their signaling. Interestingly, there 
does not appear to be a dose response relationship for the 
effects of pasireotide in Cushing’s disease.
The future place of pasireotide in patients with Nel-
son’s syndrome needs to be balanced by its side effects, 
especially hyperglycemia. Hyperglycemia was a frequent 
adverse event associated with pasireotide treatment in this 
study with six out of seven patients developing abnormal 
fasting glucose and either new or worsening diabetes. 
Fasting glucose and HbA1c continued to increase during 
treatment in spite of the clinicians’ attempts to treat this 
medically and one patient withdrew due to hyperglycemia. 
Similarly high rates of hyperglycemia were reported in 
49% of patients treated with LAR pasireotide [35] and 73% 
of patients treated with s.c. pasireotide (1200 or 1800 μg 
daily) for CD [24]; in this study 6% of patients discon-
tinued treatment due to a hyperglycemia related adverse 
event and 46% had to start a new anti-diabetic medica-
tion. The significant fall in insulin levels observed in our 
study is consistent with suppression of insulin secretion 
from beta cells of the pancreas, in keeping with the known 
action of pasireotide at the somatostatin subtype 5 recep-
tors on these cells [36]. The observed hyperglycemia fol-
lowing pasireotide treatment is due to the suppression of 
insulin and incretin response (glucagon-like peptide 1 
and glucose-dependent insulinotropic polypeptide) [36]. 
Greater physician awareness of the pasireotide-associated 
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hyperglycemia and more aggressive management of glu-
cose-related AEs may make pasireotide more acceptable 
for managing this challenging condition [37]. Active mon-
itoring and management of glucose homeostasis is needed 
and patients counseled about this prior to therapy.
The main limitations of this study are the small patient 
numbers, with this reflecting on overall generalizability, 
and the fact that half the patients did not complete the 
study. Although the recruitment target was not met, the 
results confirm a statistically significant biochemical effect 
even in this small patient size. Plasma ACTH levels before 
the morning administration of glucocorticoid dose (ACTH 
0 h) are most commonly used for monitoring of patients 
with Nelson’s syndrome and our results show statistically 
significant reductions during treatment with the robust 
GLM test. A non-significant trend of reduction of plasma 
ACTH levels 2 h post glucocorticoid dose with GLM is 
likely due to lack of power and lower baseline levels of 
ACTH after glucocorticoid administration (mean base-
line ACTH 0 h 1823 ± 1286 ng/l vs. mean baseline ACTH 
2 h 1100 ± 987 ng/l). Three of the patients who showed 
response received radiation therapy 6–16 years prior to 
study entry and in the absence of historic ACTH levels a 
small lasting effect of radiation treatment on ACTH levels 
cannot be definitely excluded, but given the rapid fall in 
ACTH seen on treatment and the very long time period 
from radiation administration a significant contributing 
effect of radiation is unlikely. Treatment for periods longer 
than this study protocol (7 months) are likely needed to 
investigate the effect of treatment in tumor volume. The 
strengths of the study lie in the prospective design and the 
statistically significant evidence of biochemical response 
to medical therapy.
In conclusion, pasireotide treatment (s.c. and LAR) was 
effective in reducing ACTH levels in Nelson’s syndrome and 
might represent a potential treatment on an individualized 
basis as treatment options are limited; the lack of complete 
consistency of response precludes making firm recommen-
dations. If considered, active monitoring and management 
of glucose homeostasis is mandatory. The patients who 
responded did so soon after initiation of pasireotide, and 
thus it would be reasonable to consider a complete lack of 
response after 2 months of treatment as a failure of response 
and therapy be discontinued. The LAR preparation appears 
as effective as the s.c. preparation and is likely to be more 
acceptable to patients. It would seem reasonable to com-
mence therapy at a lower dose and escalate if tolerated, as 
there appears to be no clear relationship between dose and 
effect. Our study is limited, however, by the small sample 
size and duration of therapy, precluding wide generalizabil-
ity, and further studies are needed of longer duration (12–24 
months) in greater numbers to formally assess the impact of 
pasireotide in Nelson’s syndrome.
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